---
title: "300255.SZ (300255.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300255.SZ/news.md"
symbol: "300255.SZ"
name: "300255.SZ"
parent: "https://longbridge.com/en/quote/300255.SZ.md"
datetime: "2026-05-20T11:38:38.812Z"
locales:
  - [en](https://longbridge.com/en/quote/300255.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300255.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300255.SZ/news.md)
---

# 300255.SZ (300255.SZ) — Related News

### [Sharp Stock Price Drop and Frequent Cash-Outs by Chairman's Father: CSBIO Responds](https://longbridge.com/en/news/286417171.md)
*2026-05-14T12:32:38.000Z*
> On May 14, CSBIO's stock price plunged 6.84%, closing at 42.51 yuan per share. The company received a regulatory letter 

### [CSBIO: Has not conducted head-to-head clinical trials of Abemaciclib with other similar drugs](https://longbridge.com/en/news/285681321.md)
*2026-05-08T07:30:29.000Z*
> On May 8th, CSBIO stated on the interactive platform that the company has not conducted head-to-head clinical trials of 

### [CSBIO: Sodium Heparin Injection has obtained the drug registration certificate in Belarus](https://longbridge.com/en/news/285332464.md)
*2026-05-06T07:51:03.000Z*
> CSBIO recently announced that its heparin sodium injection has obtained a drug registration certificate in Belarus. This

### [](https://longbridge.com/en/news/285295220.md)
*2026-05-06T01:56:32.000Z*
> The ChiNext Index rose by over 3%, LONGSYS increased by nearly 20%, Ingenic and Range Technology rose by over 10%, while

### [](https://longbridge.com/en/news/285295879.md)
*2026-05-06T01:53:13.000Z*
> The A-share innovative drug sector has fluctuated and strengthened, with TONGHUA GOLDEN-HORSE hitting the daily limit, O

### [CSBIO released its first-quarter performance, with a net profit attributable to the parent company of 5.871 million yuan, an increase of 55.21%](https://longbridge.com/en/news/284391985.md)
*2026-04-28T14:06:39.000Z*
> CSBIO released its first quarter report for 2026, with operating revenue of 256 million yuan, a year-on-year decrease of

### [CSBIO: Heparin Sodium Injection has obtained the drug registration certificate in Kyrgyzstan](https://longbridge.com/en/news/282803988.md)
*2026-04-15T07:57:43.000Z*
> CSBIO announced that it recently received notification that the company's heparin sodium injection has obtained a drug r

### [CSBIO: Aibennapeptide is currently under review for listing](https://longbridge.com/en/news/282643770.md)
*2026-04-14T07:06:09.000Z*
> On April 14th, CSBIO stated on the interactive platform that Abemaciclib is currently under review for listing. For spec

### [The sales guidance growth for 2026 is optimistic, the innovative drug concept is experiencing a rebound, and Junshi Biosciences is favored again](https://longbridge.com/en/news/282486262.md)
*2026-04-13T02:54:11.000Z*
> On April 13th, the innovative drug concept rebounded, with Junshi Biosciences rising over 10%. Data from the National Me